Quarter Business Highlights

For the nine months ended December 31, 2023, sales revenue increased by 2.6% year on year to 112,728 million yen. Operating income was 30,450 million yen, an increase of 8.8% year on year, and profit before tax was 30,973 million yen, an increase of 9.0% year on year. Net income attributable to owners of parent was 24,002 million yen, an increase of 5.9% year on year. The factors behind the results include a decrease in the ratio of cost to sales caused by the increase in sales revenue and an improvement in the sales mix. The Pharmaceuticals Business recorded a sales revenue of 94,606 million yen, an increase of 1.6% year on year. This increase can be explained mainly by growth in sales of Viltepso, a treatment for Duchenne muscular dystrophy (DMD), sales of Uptravi, a treatment for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), and the royalty income from overseas sales of the latter product, despite the impacts of drug price revisions and the generic alternatives. The Functional Food Business recorded a sales revenue of 18,121 million yen, an increase of 7.7% year on year, due to an increase in sales of protein preparations, supplements, and other products.